7-((4-ethylpiperazin-1-yl)(4-(trifluoromethyl)phenyl)methyl)-8-methoxyquinoline | 1520081-27-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 7-((4-ethylpiperazin-1-yl)(4-(trifluoromethyl)phenyl)methyl)-8-methoxyquinoline
• 英文别名: 7-[(4-ethylpiperazin-1-yl)-[4-(trifluoromethyl)phenyl]methyl]-8-methoxyquinoline
• CAS: 1520081-27-9
• 化学式: C₂₄H₂₆F₃N₃O
• 分子量: 429.485
• InChiKey: YEXAAULNOYDZND-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  31
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  28.6
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  重氮甲烷 、 7-[(4-乙基-1-哌嗪基)[4-(三氟甲基)苯基]甲基]-8-喹啉醇 以 乙醚 为溶剂， 反应 1.0h， 以to provide 7-((4-ethylpiperazin-1-yl)(4-(trifluoromethyl)phenyl)methyl)-8-methoxyquinoline (5.0 mgs, 8% yield) in high purity (>95%)的产率得到7-((4-ethylpiperazin-1-yl)(4-(trifluoromethyl)phenyl)methyl)-8-methoxyquinoline
  参考文献：
  名称：

  METHODS AND COMPOSITIONS USEFUL FOR TREATING DISEASES INVOLVING BCL-2 FAMILY PROTEINS WITH ISOQUINOLINE AND QUINOLINE DERIVATIVES

  摘要：

  本发明涉及一种用于癌症治疗的组合物和方法，例如造血系统癌症（例如B细胞淋巴瘤）。在其他方面，本发明提供了治疗特定类型造血系统癌症（如B细胞淋巴瘤）的方法，使用披露的一种或多种化合物的组合，例如26S蛋白酶抑制剂，例如博特泽米布。在另一个方面，本发明涉及使用披露的化合物进行自身免疫治疗的方法。在另一个方面，本发明涉及识别化合物的方法，例如BH3类似物类化合物，具有预测体内对B细胞淋巴瘤肿瘤和其他癌症以及自身免疫疾病有效性的独特体外性质。

  公开号：

  US20160038503A1

文献信息

• [EN] METHODS AND COMPOSITIONS USEFUL FOR TREATING DISEASES INVOLVING BCL-2 FAMILY PROTEINS WITH ISOQUINOLINE AND QUINOLINE DERIVATIVES<br/>[FR] MÉTHODES ET COMPOSITIONS UTILES DANS LE TRAITEMENT DE MALADIES FAISANT APPEL À DES PROTÉINES DE LA FAMILLE BCL-2 ET DES DÉRIVÉS D'ISOQUINOLÉINE ET DE QUINOLÉINE
  申请人：RICHARD DAVID J

  公开号：WO2014081953A1

  公开（公告）日：2014-05-30

  The present invention relates to a compositions for and methods for cancer treatment, for example, hematopoietic cancers (e.g. B-cell Lymphoma). In other aspects, the invention provides methods for treating particular types of hematopoietic cancers, such as B-cell lymphoma, using a combination of one or more of the disclosed compounds and, for example, 26S proteasome inhibitors, such as, for example, Bortezomib. In another aspect the present invention relates to autoimmune treatment with the disclosed compounds. In another aspect, this invention relates to methods for identifying compounds, for example, compounds of the BH3 mimic class, that have unique in vitro properties that predict in vivo efficacy against B-cell lymphoma tumors and other cancers as well as autoimmune disease.

  本发明涉及用于癌症治疗的组合物和方法，例如造血系统癌症（如B细胞淋巴瘤）。在其他方面，该发明提供了治疗特定类型的造血系统癌症（如B细胞淋巴瘤）的方法，使用公开化合物中的一个或多个与例如26S蛋白酶抑制剂（例如Bortezomib）的组合。另一方面，本发明涉及使用公开化合物进行自身免疫治疗。另一方面，本发明涉及用于鉴定化合物的方法，例如BH3类模拟化合物，其具有预测体内有效性对抗B细胞淋巴瘤肿瘤和其他癌症以及自身免疫疾病的独特体外特性。
• METHODS AND COMPOSITIONS USEFUL FOR TREATING DISEASES INVOLVING BCL-2 FAMILY PROTEINS WITH QUINOLINE DERIVATIVES
  申请人：Eutropics Pharmaceuticals, Inc.

  公开号：US20150133450A1

  公开（公告）日：2015-05-14

  The present invention relates to compositions and methods for cancer treatment comprising compounds of Formulae I, II, and III. In some aspects, the invention relates to the treatment of B-cell Lymphoma or other hematopoietic cancers. In other aspects, the invention provides methods for treating particular types of hematopoietic cancers, such as, for example, B-cell lymphoma, using a combination of one or more compounds of Formulae I, II, and III. Combination therapy with, for example, 26S proteasome inhibitors, such as, for example, Bortezomib, are also included. In another aspect the present invention relates to autoimmune treatment with compounds of Formulae I, II, and III. In another aspect, this invention relates to methods for identifying compounds, for example, compounds of the BH3 mimic class, that have in vitro properties that predict in vivo efficacy against B-cell lymphoma tumors and other cancers as well as autoimmune disease.

  本发明涉及公式I、II和III化合物的组合物和用于癌症治疗的方法。在某些方面，本发明涉及治疗B细胞淋巴瘤或其他造血系统癌症的方法。在其他方面，本发明提供了治疗特定类型造血系统癌症的方法，例如，使用公式I、II和III化合物的一种或多种组合物治疗B细胞淋巴瘤。还包括与26S蛋白酶体抑制剂（例如Bortezomib）的组合疗法。在另一个方面，本发明涉及使用公式I、II和III化合物的自身免疫治疗。在另一个方面，本发明涉及识别化合物的方法，例如BH3类似物类化合物，具有预测体外有效性对抗B细胞淋巴瘤肿瘤和其他癌症以及自身免疫疾病的体内功效的特性。
• Methods and compositions useful for treating diseases involving Bcl-2 family proteins with isoquinoline and quinoline derivatives
  申请人：Eutropics Pharmaceuticals, Inc.

  公开号：US10413549B2

  公开（公告）日：2019-09-17

  The present invention relates to a compositions for and methods for cancer treatment, for example, hematopoietic cancers (e.g. B-cell Lymphoma). In other aspects, the invention provides methods for treating particular types of hematopoietic cancers, such as B-cell lymphoma, using a combination of one or more of the disclosed compounds and, for example, 26S proteasome inhibitors, such as, for example, Bortezomib. In another aspect the present invention relates to autoimmune treatment with the disclosed compounds. In another aspect, this invention relates to methods for identifying compounds, for example, compounds of the BH3 mimic class, that have unique in vitro properties that predict in vivo efficacy against B-cell lymphoma tumors and other cancers as well as autoimmune disease.

  本发明涉及一种治疗癌症的组合物和方法，例如造血癌症（如B细胞淋巴瘤）。在其他方面，本发明提供了使用一种或多种已公开化合物与例如 26S 蛋白酶体抑制剂（例如硼替佐米）组合治疗特定类型造血癌症（如 B 细胞淋巴瘤）的方法。在另一方面，本发明涉及用所公开的化合物进行自身免疫治疗。在另一个方面，本发明涉及鉴定化合物的方法，例如，BH3模拟类化合物，该化合物具有独特的体外特性，可预测对B细胞淋巴瘤肿瘤和其他癌症以及自身免疫性疾病的体内疗效。
• Methods and compositions useful for treating diseases involving Bcl-2 family proteins with quinoline derivatives
  申请人：Eutropics Pharmaceuticals, Inc.

  公开号：US10765673B2

  公开（公告）日：2020-09-08

  The present invention relates to compositions and methods for cancer treatment comprising compounds of Formulae I, II, and III. In some aspects, the invention relates to the treatment of B-cell Lymphoma or other hematopoietic cancers. In other aspects, the invention provides methods for treating particular types of hematopoietic cancers, such as, for example, B-cell lymphoma, using a combination of one or more compounds of Formulae I, II, and III. Combination therapy with, for example, 26S proteasome inhibitors, such as, for example, Bortezomib, are also included. In another aspect the present invention relates to autoimmune treatment with compounds of Formulae I, II, and III. In another aspect, this invention relates to methods for identifying compounds, for example, compounds of the BH3 mimic class, that have in vitro properties that predict in vivo efficacy against B-cell lymphoma tumors and other cancers as well as autoimmune disease.

  本发明涉及由式I、II和III化合物组成的治疗癌症的组合物和方法。在某些方面，本发明涉及 B 细胞淋巴瘤或其他造血癌症的治疗。在其它方面，本发明提供了使用一种或多种式I、II和III化合物组合治疗特定类型造血癌症，例如，B细胞淋巴瘤的方法。还包括与例如 26S 蛋白酶体抑制剂（如硼替佐米）的联合疗法。在另一方面，本发明涉及用式 I、II 和 III 的化合物进行自身免疫治疗。在另一方面，本发明涉及鉴定化合物的方法，例如，BH3模拟类化合物，其体外特性可预测体内对B细胞淋巴瘤肿瘤和其他癌症以及自身免疫性疾病的疗效。
• METHODS AND COMPOSITIONS USEFUL FOR TREATING DISEASES INVOLVING BCL-2 FAMILY PROTEINS WITH ISOQUINOLINE AND QUINOLINE DERIVATIVES
  申请人：RICHARD David

  公开号：US20160038503A1

  公开（公告）日：2016-02-11

  The present invention relates to a compositions for and methods for cancer treatment, for example, hematopoietic cancers (e.g. B-cell Lymphoma). In other aspects, the invention provides methods for treating particular types of hematopoietic cancers, such as B-cell lymphoma, using a combination of one or more of the disclosed compounds and, for example, 26S proteasome inhibitors, such as, for example, Bortezomib. In another aspect the present invention relates to autoimmune treatment with the disclosed compounds. In another aspect, this invention relates to methods for identifying compounds, for example, compounds of the BH3 mimic class, that have unique in vitro properties that predict in vivo efficacy against B-cell lymphoma tumors and other cancers as well as autoimmune disease.

  本发明涉及一种用于癌症治疗的组合物和方法，例如造血系统癌症（例如B细胞淋巴瘤）。在其他方面，本发明提供了治疗特定类型造血系统癌症（如B细胞淋巴瘤）的方法，使用披露的一种或多种化合物的组合，例如26S蛋白酶抑制剂，例如博特泽米布。在另一个方面，本发明涉及使用披露的化合物进行自身免疫治疗的方法。在另一个方面，本发明涉及识别化合物的方法，例如BH3类似物类化合物，具有预测体内对B细胞淋巴瘤肿瘤和其他癌症以及自身免疫疾病有效性的独特体外性质。